Two sizable issuers went public this past week and featured the best first-day pop for a billion-dollar IPO in Renaissance’s ...

Body image is part physical and part mental. If weight loss alone isn't helping, strategies from body image psychology can ...

But behind the headlines and hashtags lies a disturbing trend that deserves urgent attention: the rise of compounded GLP-1s ...

Omada Health went public on the Nasdaq Friday, marking the second digital health company to do so after a post-pandemic ...

Shares in Omada Health (NASDAQ:OMDA) rose 21% in their Nasdaq debut on Friday, closing at US$23 after pricing at US$19 in the ...

Weight-loss injections are taking off in Switzerland. But despite obesity being more prevalent among men, it is women who are ...

Fresh from a $150 million IPO on Wall Street, Omada Health CEO Sean Duffy shares his thoughts on speed bumps, GLP-1s, staying ...

After reviewing several large epidemiological studies, clinical trial and in-market data, EMA’s Pharmacovigilance Risk Assessment Committee has concluded non-anterior ischemic optic neuropathy is a ...

Treatment should be stopped if nonarteritic anterior ischemic optic neuropathy, which can cause vision loss, is diagnosed.

GLP-1s are gaining interest for their impact on weight, blood sugar, and possibly mood in bipolar disorder. Here’s what ...

Omada Health is making its public-market debut, propelled by Americans’ renewed focus on how weight affects physical health.